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Abstract
Purpose The subretinal Alpha IMS visual implant is a
CE-approved medical device for restoration of visual
functions in blind patients with end-stage outer retina
degeneration. We present a method to test the function of
the implant objectively in vivo using standard elec-
troretinographic equipment and to assess the devices’
parameter range for an optimal perception.
Methods Subretinal implant Alpha IMS (Retina
Implant AG, Reutlingen, Germany) consists of 1500
photodiode-amplifier-electrode units and is implanted
surgically into the subretinal space in blind retinitis
pigmentosa patients. The voltages that regulate the
amplifiers’ sensitivity (Vgl) and gain (Vbias), related to the
perception of contrast and brightness, respectively, are
adjusted manually on a handheld power supply device.
Corneally recorded implant responses (CRIR) to full-
field illumination with long duration flashes in various
implant settings for brightness gain (Vbias) and ampli-
fiers’ sensitivity (Vgl) are measured using electroretino-
graphic setup with a Ganzfeld bowl in a protocol of
increasing stimulus luminances up to 1000 cd/m2.
Results CRIRs are a meaningful tool for assessing the
transfer characteristic curves of the electronic implant
in vivo monitoring the implants’ voltage output as a
function of log luminance in a sigmoidal shape.
Changing the amplifiers’ sensitivity (Vgl) shifts the
curve left or right along the log luminance axis.
Adjustment of the gain (Vbias) changes the maximal
output. Contrast perception is only possible within the
luminance range of the increasing slope of the function.
Conclusions The technical function of subretinal
visual implants can be measured objectively using a
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standard electroretinographic setup. CRIRs help the
patient to optimise the perception by adjusting the gain
and luminance range of the device and are a useful tool
for clinicians to objectively assess the function of
subretinal visual implants in vivo.
Keywords Neuroprosthetics  Retinitis pigmentosa 
Artificial vision  Hereditary retinal diseases 
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Introduction
Several therapeutic approaches are under develop-
ment for hereditary degeneration of the outer retina,
including gene-therapy [1–3], electrostimulation [4],
and microelectronic visual implants [5–8].
In this paper, we present a method to assess the
transfer characteristics of the subretinal visual Retina
Implant Alpha IMS objectively in vivo. Retina
Implant Alpha IMS (Retina Implant AG, Reutlingen,
Germany, Fig. 1) is a CE-approved medical device
which can partially replace lost photoreceptor function
by performing the light-to-voltage conversion. This
results in a current injection and a charge transfer to
retinal neurons at each of its 1500 electrodes, mainly
stimulating bipolar cells [12, 13]. The Alpha IMS
implant can be implanted in blind patients suffering
from hereditary degeneration of photoreceptors such
as retinitis pigmentosa. Because in retinitis pigmen-
tosa the inner retina and the remaining visual pathway
Fig. 1 Subretinal alpha
IMS implant (Retina
Implant AG, Reutlingen,
Germany). a The subdermal
receiver coil behind the ear
provides power and
forwards control signals via
a subdermal cable and a thin
intraocular foil to the chip in
the eye. b The external
transmitter coil is
magnetically kept in place
above the subdermal coil
behind the ear and provides
power and signals via
transdermal electric
induction. c The chip is
placed surgically beneath
the fovea and contains 1500
pixels (independent
microphotodiode-amplifier-
electrode elements) on a
3 mm 9 3 mm area. d Via a
thin black cable, a small




can be adapted manually.
(Figure modified from
Stingl et al. [6]
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stay largely functional even during end-stage condi-
tions [8], spatially ordered electrical stimulation can
activate the natural visual pathway from the bipolar
cells onward. Patients report to perceive an electrical
grey-scale image within a square-shaped 11 9 11
visual field [6, 9]. To date, the subretinal visual
implant has been shown to restore useful visual
functions in blind patients as well as to provide a
visual acuity of up to 20/546 (decimal 0.037) and
improve performance in tasks such as object localisa-
tion and recognition in daily life [5, 6, 10]. From 2010
to 2013, the implant was applied in a multicentre
clinical trial in 29 patients with end-stage hereditary
retinal disease (www.clinicaltrials.gov,
NCT01024803) [6, 10, 11].
The active subretinal chip is surgically implanted
into the subretinal space (Fig. 1c), connected via a
subdermal cable to a retroauricular receiver coil
(Fig. 1a) that is powered inductively via an epidermal
transmitter coil controlled by an external handheld
unit (Fig. 1b, d), held in place by a subdermal magnet.
The active subretinal chip is a microphotodiode array
(MPDA) that consists of 1500 independent micropho-
todiode-amplifier-electrode units. At each electrode of
the MPDA, rectangular anodic voltage pulses are
applied and current is injected into the retina [5],
where the amplitude of the voltage pulses depends on
the luminance present at the corresponding micropho-
todiode. The function of the corresponding charge
output per pixel plotted against the logarithm of
illuminance, the so-called transfer characteristic curve
in vitro, is being measured in vitro after manufacturing
the implant and has a sigmoidal shape. The steep part
of the sigmoid covers approximately two logarithmic
units and represents the range where different illumi-
nations are translated into a graded electrical output of
different magnitude, building a basis for contrast
perception.
In contrast to natural vision, there is no luminance
adaptation of the photodiode system. Instead, the
transfer characteristic curve can be shifted across the
luminance spectrum by adjusting the control voltage
(Vgl), allowing an adjustment of contrast perception to
ambient light levels. Additionally, the amplifier gain
can be adjusted using a second control voltage (Vbias),
changing the slope and the maximal voltage output,
(brightness) of the perception. The transfer character-
istic curves are measured in vitro for various combi-
nations of the Vgl and Vbias parameters. A patient with
the Retina Implant Alpha IMS can manually adjust
both parameters on the handheld unit (Fig. 1d) in order
to optimise his/her visual perception. This optimisa-
tion requires some training supported by a specialised
ophthalmologist, clinical engineer, or mobility trainer
during the first few days after implant activation.
Here, we describe a new method to test the transfer
characteristic curve of the subretinal visual implant
Alpha IMS objectively in vivo using standard elec-
troretinographic equipment with long duration light
flashes.
Generated by the voltage pulses of the chip, current
spreads from the electrodes through the retina and
tissue back to the return electrode and at each point
along the current path a voltage drop occurs. Conse-
quently, at the cornea, voltage pulses can be recorded
with an amplitude that correlates with the amplitude of
the chip output voltage, which have a time course that
is congruent to the time course of the chip-induced
current pulses. We measured these corneally recorded
implant responses (CRIR) to full-field stimulation
with standard electroretinographic equipment picking
up the voltage at the cornea by a corneal electrode.
This method presents (1) an important measurement to
determine the optimal settings according to luminance
conditions and (2) an objective diagnostic tool for
measuring the implant function in vivo.
Materials and methods
Alpha IMS subretinal visual implant
The subretinal Alpha IMS implant (Fig. 1) is a CE-
approved medical device developed for the restoration
of visual functions in blind patients suffering from
photoreceptor degeneration. A 1500-pixel chip forms
the implant’s core. Each pixel is composed of a
photodiode receiving the incoming light, a differential
amplification circuit to provide adequate stimulation
current, and a metal electrode of 50 lm 9 50 lm to
transfer charges to the adjacent retinal layers. The chip
is approximately 3 mm 9 3 mm in size and 70 lm
thick, mounted on polyimide foil (thickness approx.
20 lm) and encapsulated with an electrically isolating
biocompatible layer [5, 6]. The polyimide foil exits the
subretinal space in the upper temporal periphery
through the choroid and the sclera, where it is
connected to the power supply cable, leading to the
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retroauricularly placed subdermal receiver coil
(Fig. 1a, c). Here, an external transmitter coil placed
on top of the skin behind the ear (Fig. 1b), held in
place by a magnet permits an inductive transfer of
energy and control signals from the handheld unit
(Fig. 1d) through the skin to the implant.
The external handheld unit (Fig. 1d) has two knobs.
One knob changes the gain of the amplifiers, i.e., it
compresses or stretches the transfer characteristic
function to a lower or higher maximum output by
changing the Vbias voltage, thereby changing the
maximal brightness perception. The other knob varies
the absolute sensitivity (theVgl voltage), i.e., it shifts the
transfer function along the range of luminances. Both
knobs have arbitrary values from 0 to 99 indicated on a
small display. The range of voltage provided within
these 100 units is adjusted individually for each patient
in the present version of the power supply.
The chip typically records and transfers images 5 times
per second (a working frequency of 5 Hz, adjustable from
1 to 20 Hz) and provides a ‘‘point-by-point electrical
image’’ of the luminance distribution. The output signal of
each electrode of the implant is a monophasic anodic
voltage pulse of 1 ms (adjustable from 0.1 to 2 ms). Due
to the capacitive properties of the interface between
electrode and retina, the voltage pulse gives rise to a
biphasic current pulse. The current spreads through the
retina and depolarises the bipolar cells [12, 13]. From the
bipolar cells onward, the signal is processed via the
remaining visual pathway. The perceived image is a
flickering image in grey levels within a squared field
spanning 15 across corners [6, 10].
Patient characteristics
Patients who receive the subretinal visual implants suffer
from end-stage hereditary degeneration of the outer
retina, e.g., retinitis pigmentosa. Between 2010 and
2013, 29 patients worldwide received the Retina Implant
Alpha IMS in their least functional eye in a multicentre
clinical trial (www.clinicaltrials.gov, NCT01024803)
[9]. Any additional diseases of the eye that affect the
visual pathway or clear optical media are contraindica-
tions for a subretinal visual implant (e.g., glaucoma,
diabetic retinopathy, occipital stroke, profound ambly-
opia, congenital blindness, corneal opacities). Written
informed consent in accordance with Declaration of
Helsinki was obtained from all participants. The study
was approved by the local ethics committee.
Recording protocol
CRIRs (see Fig. 2) were obtained using a
ColorDome controlled by an Espion E2 module
(Diagnosys LLC, Cambridge, UK). The pupil was
dilated to guarantee the highest possible illumination
of the MPDA surface. The partner eye was occluded,
and its responses were not recorded. DTL electrodes
[14, 15] (conjunctival, active electrode) and two gold-
cup electrodes (VIASYS Healthcare, Warwick, UK)
were positioned in the same way as for full-field
electroretinography: with one on the forehead (ground
electrode) and a second temporal to the lateral canthus
of the study eye (reference electrode). Skin-cleaning
procedures with an abrasive gel were performed
before electrode positioning to achieve an accept-
able impedance level (B5 kX). Any corneal electrode
can be used; however, postoperatively the DTL is the
least invasive.
Dark adaptation was not necessary (as no adapta-
tion mechanisms are present in the MPDA), but the
room was completely darkened during the measure-
ments to avoid contributions from room illumination
to CRIR. The MPDA is sensitive to infrared light.
Therefore, the ColorDome internal camera, which
uses infrared light, was switched off for all
measurements.
The ERG protocol consisted of 9 steps of long
duration flashes (350 ms), with increasing stimulus
luminance of white light from 0.1 to 1000 photopic cd/
m2 in 0.5 log steps using white mixed light (LED
spectrum: blue 470 nm, amber 594 nm, green
513 nm, red 635 nm). The photodiodes cover the
visible light spectrum and partially infrared irradiation
(sensitivity range approx. 400–950 nm). Each 9-step
procedure was performed for a specified contrast (Vgl)
and gain (Vbias) combination setting of the implant.
The working frequency (5 Hz) and pulse duration of
the chip (1 ms) were kept constant for the entire
measurement, so that for each step, one or two chip
responses were recorded. All details of the protocol
settings are described in Supplementary Table 1.
The Espion E2 module uses a DC amplifier with an
input range of the ±0.5 V (CMRR[ 100 dB at
50 Hz) and a fixed gain of 10. Signals are digitised
using a 16 bit ADC with 12 bit DC offset (internal bias,
which creates an offset voltage, stored as a 12 bit
value). The recordings were observed continuously. A
saturation of the recorded signal was not observed
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(would present as a ceiling flatline in the shape of the
signal).
For recording the CRIR, a sampling frequency of
5 kHz was used and signals were filtered using a build-
in digital band-pass filter (second order cascaded
Bessel filter) with a low cut-off frequency of 0.312 Hz
and high cut-off frequency of 300 Hz. During the
examination, recorded signals are observed continu-
ously for potential artefacts. In case of an artefact, the
particular luminance step is repeated.
The amplitudes were read off the screen and
manually documented in an Excel worksheet to create
CRIR values (see Results).
Results
A typical pulse shape of the voltage at the cornea
generated by a 1 ms anodic voltage pulse of the chip
and recorded with the ERG equipment is shown in
Fig. 2 Examples of in vivo CRIR recordings with 9 luminance
steps showing a typical pulse shape with the sampling frequency
of 5 kHz (black dots). The 1 ms anodic voltage pulse output
from the implant electrodes results in a slowly rising current that
shows an overshoot in the opposite direction after pulse offset
and a subsequent return to the baseline. The full-field luminance
levels for each particular step are indicated above each curve.
With increasing luminance, the amplitude of the CRIR increases
showing the dynamic range of the particular chip settings (here
Vgl = 20, Vbias = 65). These amplitudes are then documented
as a CRIR curve (as shown in Fig. 3)
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Fig. 2. This CRIR is the typical pulse response of the
amplifier and Bessel filter to the biphasic voltage pulse
on the cornea.
A series of CRIRs (Fig. 2) evoked by increasing steps
of stimulus luminance allows to determine the transfer
characteristic curve of the Retina Implant Alpha IMS
in vivo, resulting in a sigmoid curve describing the
corneally recorded voltage as a function of log lumi-
nance (Figs. 3, 4). In Fig. 3, examples of four patients
are shown as separate diagrams. A single curve in each
of the diagrams represents a CRIR transfer function
recorded with specific Vgl/Vbias combination. The
respective Vgl/Vbias values of the colour-coded curves
are shown in the left upper part of the figure. The CRIR
measurement in each patient consists of several curves
based on different Vgl/Vbias combinations.
As the amplifier in the MPDA covers only a range
of approximately two logarithmic units of luminance,
its sensitivity has to be adjusted to cover the range
prevailing ambient luminance. Turning the sensitivity
knob of the handheld control box (change in Vgl 0–99)
shifts the CRIR curve left or right (Fig. 4b). Variation
of the amplifiers’ gain (Vbias 0–99) changes the
maximal output of the chip, thus changing the slope
and the saturation level (Fig. 4c).
Luminance steps either within the subthreshold
region or saturation region of the CRIR function
cannot be resolved by the implant and are therefore not
seen by the patient; only if the luminance interval is
within the steep slope of the sigmoidal curve contrast
border recognition is possible.
Although the maximal output in the saturation
region of each curve tends to be proportional to the
Vbias value in vitro, a Vbias value between 55 and 75
typically produces a maximal output voltage in vivo;
other Vbias values (both higher and lower) reduce the
maximal outputs (Fig. 4c).
An example of settings, based on CRIRs measured
in vivo for a visual test of grey level differentiation, is
given in supplementary Fig. 1.
Fig. 3 CRIR as transfer characteristic curves in vivo in various
combinations of the Vgl/Vbias settings that define the MPDA-
amplifiers’ sensitivity and gain, respectively, from four patients
measured at various time points during the 1-year follow-up
visits. a patient C9, b patient C10, c patient C12 d patient C7.
The inserted tables show values for Vgl/Vbias
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Discussion
CRIRs are a tool for testing electronic subretinal visual
implants in vivo. By recording a series of CRIRs in
response to increasing full-field luminance (Fig. 2),
the input/output function (Fig. 3) of the implant can be
assessed. As the amplitude of the corneally recorded
voltage correlates with the amplitude of the MPDA
output voltage, the in vivo transfer function obtained
from the CRIR amplitudes resembles the in vitro
transfer function. The CRIRs cannot measure the
voltage output of the device directly, but can evaluate
the influence of the luminance, Vbias and Vgl variation
on the measured voltage, thus monitoring the main
technical function of the implant—the transfer of
illuminance on the MPDA surface into voltage and
current, respectively, according to the transfer
function.
Amplitude and shape of the CRIRs depend on many
factors and do not correlate solely with the actual
voltage output of the device. The capacity of the
electrodes on the MPDA, the contact surface between
the electrodes and the retinal tissue, the resistance of the
tissue itself and the impedance of the ERG electrode
influences the CRIRs. Of great importance is the
characteristic of the Bessel filter of ERG equipment.
Mathematically spoken, the signal output from the ERG
system is the convolution of the impulse response of the
Bessel filter with the voltage pulse on the cornea. This
gives rise for a signal delay and a pulse broadening.
Thus, as the recorded signal is a surrogate marker of
many factors, the shape of the corneally recorded
waveform cannot be used for a detailed analysis of the
MPDA and its functional integration into the retina
(Fig. 5). To examine the contact between the MPDA
and the retina, high-resolution OCT can be used.
Especially fluid between the retina and the microchip or
detachment from the chip by subretinal debris after the
surgery or by pigment clumps is visible in OCT.
However, the amplitude of the signal output of
ERG system is linearly dependent on the amplitude of
the MPDA output. Thus, the CRIRs are well suited to
verify the transfer function of the MPDA in vivo.
These curves allow advising the patient during the
learning phase in order to help him or her to more
easily find optimal settings of brightness and contrast,
preparing the patient for optimal adjustment of the
settings for daily use. Before measuring visual func-
tions on a monitor screen or in daily life, the examiner
chooses a particular input/output function of the
implant by selecting a Vgl/Vbias combination that
allows the patient to optimally distinguish luminance
contrasts in a particular environment. This procedure,
based on recorded CRIRs, compensates for the absent
automatic adaptation to ambient luminance conditions
in artificial vision, in contrast to natural vision.
Furthermore, it is important for objectively mea-
suring the visual implants’ function.
CRIRs are recorded immediately after the implant
is turned on for the first time to help to optimally set
Fig. 4 a CRIR from patient C9, as taken from Fig. 4a, shows
data measured during a single trial visit; b illustrates how
changing the Vgl value shifts the curve along the luminance
range; c illustrates the change of minimum and maximum output
when altering Vbias. The values for Vgl/Vbias are shown in the
upper left corner
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the brightness and contrast parameters in a given
ambient luminance. Over time, the patient learns to
change the parameters according to the subjective
perception of brightness and contrast in order to
achieve optimal visual perception, and subsequently
CRIR is only required to control implant function over
time.
CRIRs are measured over 4–5 logarithmic units of
luminance. A maximum of luminance of 1000 cd/m2
is given due to the limitation of the electroretino-
graphical setup; however, in reality, higher luminance
conditions can be processed by the MPDA. A CRIR
curve with a steep slope allows for a better differen-
tiation between small luminance steps on the expense
of the resolvable luminance range. A flatter slope
would allow a larger luminance range on the expense
of discernible luminances (e.g., CRIR curve in Sup-
plementary Fig. 1). The subthreshold region of the
curve indicates a luminance range where no percep-
tion is possible due to low voltage output. The
saturation region indicates a luminance region in
which very bright lights of different luminance are no
longer differentiated. Differentiation of luminances is
possible only in the slope region of the curve as
different levels of grey. Patients carrying the subreti-
nal implant describe their artificial vision as blurred
images slightly flickering in various grey scales,
similar to an image from an older black-and-white
Fig. 5 Appearance, recording and characteristics of CRIRs.
Left Output voltage (Vchip), current (Ichip) and charge per pulse
(Qchip) of the MPDA. From the peak charge, the in vitro transfer
curve as a function of illuminance is obtained. Middle Related to
the current spread through the tissue, a voltage pulse at the
cornea (Vcornea) is observable. Right Voltage signal (VFilter)
recorded with the ERG system. From the peak value of this
filtered signal (CRIR), the in vivo transfer curve as a function of
luminance is obtained. Details see text
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television [6, 10], if the implant parameters are
correctly adjusted to the luminance conditions.
Recorded CRIR signals do not by themselves
indicate a subjective perception. Our experiences
show that the ‘‘lowest necessary’’ amplitude for a
perception vary inter- and intra individually between
the tests although recorded in many instances. This
link between CRIR amplitude and subjective percep-
tion threshold has not been assessed systematically
during the recordings and is thus not presented in this
manuscript.
On the other hand, the fact that the objectively
recorded CRIR signal and the subjective perception
are not necessarily correlated each time means that
CRIRs are important for objectively testing implant
function. In the case of a subjective change or sudden
perception failure, the voltage output can be tested
objectively to distinguish biological from technical
problems. For example, following a sudden loss of
perception due to a damaged wire, no CRIRs are
measurable. If the conducting wires have a suspected
loose connection, a simple examination involving
recording in all gaze directions can be very helpful; a
non-regular signal can typically be measured in some
eye positions with a loose cable connection. This case
can be distinguished from a biological problem or
retinal damage, which does not allow neuronal
processing of the normally recordable chip signal,
e.g., in cases where retinal blood perfusion is
disturbed. In such situations, degeneration has affected
the inner retina to such a degree where electrical
signals can no longer excite neurons in a spatially
ordered manner.
There are typically several Vgl/Vbias combinations
for which the slope covers a given luminance and
voltage range for each patient (Fig. 3). For safety
reasons, one should always aim for a curve that allows
for good perception with the lowest possible voltage
output. A curve in which the subthreshold region for
low luminance levels has the minimal output can be
considered optimal because dimmer light levels pro-
duce no sufficient charge transfer; bipolar cells [12]
are thus not unnecessarily stimulated in the darker
range. Similarly, if several curves that differ in their
maximum outputs in the saturation region lead to a
comparable perception of brightness, the output with
the lowest saturation voltage should be used. CRIR
curves with elevated voltages in the low luminance
part (an example can be found in Fig. 3b, curves 45/85
or 45/75) are undesirable as such settings provide
continuous stimulation also in the dark and reduce the
contrast range.
Standard equipment for clinical ERG recording is
suitable for recordings of CRIR; however, following
parameters must be met:
1. Sampling frequency of 5 kHz (at least 1 kHz)
with implant signal duration of 1 ms to allow for
sufficient data per implant response.
2. The amplitude of the response can reach up to
35 mV. The range of the input stage of the
amplifier needs to be adjusted to this signal size to
prevent saturation of the amplitude or the ana-
logue–digital converter in the ERG recording
device. If the device is not adjustable, a simple
alternator can be put between the electrode and
amplifier input. Usually commercial clinical
electrophysiological devices are built to handle
larger signals.
3. The luminance of the stimulator should reach at
least 500 cd/m2 in order to allow for testing the
implant function in typical light levels of activities
of daily living.
Conclusions
The electric function of subretinal visual microelec-
tronic implants can be measured objectively after
implantation using special protocols and standard
electroretinographic equipment. The assessment of
corneally recorded implant responses (CRIRs) is
necessary to define the optimal parameter settings
for devices such as the subretinal Retina Implant
Alpha IMS, particularly during the training period in
order to achieve optimal contrast vision, and to
objectively measure implant functions in vivo. Subop-
timal results in contrast perception and saturation can
be avoided by assessing CRIRs and using appropriate
settings of stimulation currents.
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